Medical Therapy Versus Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease  by Arbab-Zadeh, Armin
e
a
d
a
r
m
w
i
m
p
p
a
o
i
p
t
u
p
i
a
v
p
i
a
t
n
r
f
w
I
b
w
a
f
s
n
e
T
i
*
*
C
3
4
S
E
R
1
2
M
P
I
S
S
t
m
t
“
c
b
l
(
D
a
t
d
d
e
i
n
c
f
n
e
i
t
b
p
*
*
6
B
E
R
1
2
3
4
5
528 Correspondence JACC Vol. 53, No. 6, 2009
February 10, 2009:526–9qually applicable to the use of either BMI or waist circumference
s a measure of adiposity and the risk of developing cardiovascular
isease. The fact is that not all patients “at risk” develop disease,
nd not all disease occurs in patients with a known predisposing
isk factor. Regardless of how much we argue about the relative
erits of different risk stratification schemes, at the end of the day,
e are still left with considerable uncertainty in the treatment of
ndividuals.
The condition of “normal weight obesity” characterized by
uscle wasting and abdominal obesity has recently received a lot of
ress. Although this condition certainly exists, it is largely a
roblem of elderly patients. In the elderly population, age itself will
lmost certainly be a more potent risk marker than abdominal
besity. Weight loss in this population may not be of much benefit
n terms of reducing cardiovascular end points. In the middle-age
opulation where application of preventive principles is more likely
o be cost effective, normal weight obesity is uncommon and the
se of a simple metric like BMI will identify the majority of
atients at risk of obesity-related complications. Even though BMI
s an imperfect measure of fatness (particularly visceral fat), it is
lso likely that waist circumference will not be a reliable measure of
isceral fat volume in all patients. Drs. Green and Lesser both
oint out that as clinicians and scientists, we wish to have
nformation about both lean and fat body mass in our patients. I
gree with this sentiment and thank Dr. Lesser for highlighting
he large effect of lean body mass on BMI calculations. Unfortu-
ately, it is difficult or impossible to obtain measures that accu-
ately separate muscle and fat mass in the typical clinical setting.
Interestingly, most obesity researchers have used a single cutoff
or abnormal waist circumferences (102 cm in men and 98 cm in
omen) regardless of height or other measures of overall body size.
t is obvious to all of us that most biological processes do not
ehave as dichotomous variables, but rather as continuous variables
ith varying degrees of abnormality. As such, I suggest that if we
re to adopt metrics of abdominal obesity based on waist circum-
erence, that we use a graded system (i.e., mild, moderate, or
evere) that somehow takes into account body frame size (e.g.,
ormalizing waist to height).
I thank both authors for their letters. I very much welcome and
ncourage open debate and discussion about the topic of obesity.
his extraordinarily important issue that will inevitably consume
ncreasing amounts of our time and health care dollars.
Sheldon E. Litwin, MD, FACC
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ardiology
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ercutaneous Coronary
ntervention for Patients With
table Coronary Artery Disease
chömig et al. (1) reported a meta-analysis addressing the mor-
ality in patients with stable coronary artery disease randomized to
edical therapy and coronary intervention involving 17 prospec-
ive studies. The investigators concluded that based on their data,
a PCI-based invasive strategy may improve long-term survival
ompared with a medical treatment-only strategy” (1).
In addition to the numerous flaws of this analysis pointed out
y the accompanying editorial comment (2), the fundamental
imitation lies in the fact that except for the COURAGE
Clinical Outcomes Utilizing Revascularization and Aggressive
rug Evaluation) trial, none of the studies included in this
nalysis applied contemporary medical treatment. Even though
he same can be said about the interventional strategy, the
ifference is that newer medical interventions, such as high-
ose statins, dual platelet inhibition, adequate angiotensin-converting
nzyme inhibition, and beta blockade, have shown in random-
zed prospective trials to reduce the risk of death and/or
onfatal myocardial infarction compared with the standard of
are (3–5), while such randomized trials (including follow-up)
ailed to show reduction of death or myocardial infarction for
ewer interventional therapies, such as bare-metal or drug-
luting stenting (6 –9).
The report by Schömig et al. (1) therefore is misleading and
rrelevant for contemporary medical practice. We should accept
hat the COURAGE trial, despite some limitations, represents the
est evidence currently available for guiding our approach to
atients with stable coronary artery disease.
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eply
e thank Dr. Arbab-Zadeh for his interest in our paper (1). The
itle and the content of his letter show that he misinterprets the
ssence of our meta-analysis (1) by considering it as a direct
ompetition between percutaneous coronary intervention (PCI)
nd drug therapy. In the Discussion section of our article (1), we
arned against the risk of this kind of misinterpretation by writing:
It is important to note that the included randomized trials, and
onsequently the entire present meta-analysis, should not be
onsidered as a head-to-head comparison of 2 mutually exclusive
reatment strategies. On the contrary, all of them evaluated the
alue of the PCI-based strategy as an addition to medical therapy,
ecause patients in both study arms received medical treatment.”
e also acknowledged that advances in both pharmacological and
nterventional treatment of patients with coronary artery disease
ay have an impact, although the year of completion of patient
nrollment did not have a significant influence on the overall result
s shown by the meta-regression analysis.
The unique contribution of our meta-analysis was the ability to
ssess the impact of PCI on mortality, for which assessment, nonef the individual trials, including the COURAGE (Clinical
utcomes Utilizing Revascularization and Aggressive Drug Eval-
ation) trial, had sufficient power. Obviously, the performance of a
ew, large randomized trial with mortality as primary end point is
ore than welcome; but, until then, the results of our meta-
nalysis are the best available evidence on this topic and should
elp in guiding the treatment of patients with stable coronary
rtery disease.
As interventional cardiologists, we have recognized the great
linical benefits achieved with pharmacological therapy in patients
ith stable coronary artery disease. We prescribe the drugs
entioned in the letter of Dr. Arbab-Zadeh to almost all patients
rior to and after PCI. We closely work with noninterventional
ardiologists to provide optimal pharmacological and PCI-based
reatment to patients with stable coronary artery disease. However,
he benefit to these patients will be maximized if the merits of PCI
re duly recognized by the physicians who take care of patients
ith stable coronary artery disease.
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